Mirador Therapeutics and its Success

After the $10.8 Billion Cash-Out, Will the Same Team Succeed Again with a New Venture?

Mirador Therapeutics focuses on immunology and inflammatory diseases. In March 2024, the company officially launched with a massive $400 million Series A funding, ranking third in the annual biotech financing list for Europe and the U.S. Mirador Therapeutics raised this capital in just 60 days, largely due to the fact that its founding team had recently achieved the impressive $10.8 billion acquisition deal.

The $10.8 Billion Acquisition Deal: Shareholders Successfully Cash Out

On April 16, 2023, Merck announced that it would acquire Prometheus Biosciences (NASDAQ: RXDX) in a cash deal at $200 per share, valuing the total equity at about $10.8 billion.

Prometheus Biosciences' core product, PRA023, is a humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like ligand 1A (TL1A), a target associated with various intestinal inflammation and fibrosis diseases. At the time, Prometheus was developing PRA023 to treat immune-mediated diseases, including ulcerative colitis, Crohn’s disease, and had announced positive results from Phase 2 trials in December 2022.

Prometheus focused on utilizing precision medicine to develop innovative therapies for immune-mediated diseases. Its technology platform integrates multi-omics data (genomics, proteomics, etc.) with machine learning, aiming to identify biomarkers and develop targeted drugs. The company also developed biomarker-based diagnostic methods for identifying patients with high TL1A expression, improving treatment response rates. Prometheus proved that precision medicine has a place beyond oncology, attracting the attention of several large pharmaceutical companies.

Merck ultimately offered $200 per share, a 75% premium over the last closing price before the announcement (around $114), providing shareholders with an immediate cash return. After the announcement of the acquisition, Prometheus’ stock price surged nearly 70% in a single day, reflecting market approval of the terms of the deal.

The acquisition was completed in June 2023, and Prometheus officially became part of Merck. It is now conducting global Phase 3 trials for PRA023 (now known as MK-7240, tulisokibart), taking the lead in global development of TL1A-targeted drugs.

Re-entering Entrepreneurship: Continuing Precision Medicine in Immune Diseases

The founding team’s second entrepreneurial venture is a common form of talent movement after a biotech company is acquired.

After Prometheus was acquired by Merck, CEO Mark C. McKenna reflected on how Prometheus had successfully developed a therapy that increased the efficacy of inflammatory bowel disease treatment from about 15% to over 25% in clinical research, but what about the remaining 75%? He realized that this was his "unfinished business," so he decided to embark on a new adventure with his team.

After the establishment of Mirador Therapeutics, Mark C. McKenna remained as Chairman and CEO, with the same core team: Dr. Olivier Laurent as Chief Scientific Officer, Dr. Allison Luo as Chief Medical Officer, Tim Andrews as Chief Legal Officer, Vika Brough as Chief Accounting Officer, Nori Ebersole as Chief Human Resources Officer, Jordan Zwick as Chief Business Officer, and Dr. Chris Schaumburg as Vice President of Corporate Affairs—all were previously part of Prometheus.

Mirador Therapeutics continues Prometheus' precision medicine strategy in immune-mediated diseases, aiming to develop new precision drugs for immune-mediated inflammation and fibrosis diseases through its proprietary Mirador360™ development engine.

With Prometheus' success, Mirador found it easier to raise funds. CEO Mark C. McKenna stated that unlike Prometheus, which spent a year on initial fundraising, Mirador completed its funding round in about 60 days, with many investors who had also invested in Prometheus. He also mentioned that the $400 million raised exceeded expectations, enabling Mirador to build its own pipeline and advance multiple internal projects into clinical trials, while also seeking external innovation opportunities.

Mirador's Series A funding was led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other major investors include Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners LP, Venrock Healthcare Capital Partners, RTW Investments, and Alexandria Venture Investments.

Sanofi also has a TL1A-targeted drug in development, with progress relatively advanced, which could lead to direct competition with Prometheus' PRA023 (now MK-7240, tulisokibart). Sanofi's venture capital investment in Mirador Therapeutics may be influenced by this factor. Additionally, Sanofi has introduced several dual antibodies targeting this site from China.

Mirador's focus is on developing first-in-class or best-in-class precision drugs. Its proprietary Mirador360™ precision development engine leverages the latest breakthroughs in human genetics and advanced data science, designed to coordinate molecular profiles of millions of patients to discover and validate genetic associations with immune fibrosis diseases, identify new therapeutic targets, and elucidate target-target interactions and potential combinations for optimal target-target pairs. Mirador360™ also supports the development of diagnostic methods and patient stratification to enable precise clinical development.

Strategic Partnerships and Future Plans

In September 2024, Mirador announced that it was successfully listed in Endpoints News' 2024 "Endpoints 11" list of the most promising biotech startups in the pharmaceutical industry.

In November 2024, Mirador Therapeutics announced a strategic research collaboration with genetic testing leader 23andMe. Under the agreement, Mirador will use a set of targeted, de-identified genetic and phenotypic data from 23andMe's research database, combined with its proprietary Mirador360™ development engine, to drive target validation and the development of precision drugs.

23andMe's genetic and phenotypic health information database is the largest crowdsourced genetics research platform globally. Insights from the 23andMe database have led to several collaborations with pharmaceutical companies, advancing multiple drug discovery projects and generating two clinical-stage assets in immuno-oncology, as well as over 300 scientific publications. Mirador will leverage 23andMe's database to enhance its proprietary Mirador360™ development engine, which already hosts one of the largest immune-mediated disease data repositories, containing over two million human molecular profiles.

This collaboration was announced in the same month that 23andMe revealed it was laying off 40% of its staff and closing its drug development department. Due to financial difficulties, 23andMe filed for bankruptcy in March 2025 and is seeking to sell the company. Until the sale, 23andMe will continue operations as usual.

Conclusion

Mirador Therapeutics' $400 million fundraising debut reflects several trends in the current biopharmaceutical industry: the expansion of Series A funding, capital concentration, the continued heat in the autoimmune disease field, and the role of precision medicine in drug development. With the success of the $10.8 billion deal behind them, can Mirador Therapeutics replicate the success of Prometheus? Only time will tell.